Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma

NCT00946374 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Mantle-Cell Lymphoma

Interventions

DRUG: Immunochemotherapy
DRUG: High-dose BEAM plus autologous SCT
OTHER: HLA-identical allogenic SCT

Sponsor

Heidelberg University